Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer by Forrest, L M et al.
Short Communication
Comparison of an inflammation-based prognostic score (GPS)
with performance status (ECOG) in patients receiving
platinum-based chemotherapy for inoperable
non-small-cell lung cancer
LM Forrest
1, DC McMillan*,1, CS McArdle
1, WJ Angerson
1 and DJ Dunlop
2
1University Department of Surgery, Royal Infirmary, Glasgow G31 2ER, UK;
2Department of Medical Oncology, Royal Infirmary, Glasgow G31 2ER, UK
The value of an inflammation-based prognostic score (GPS) was compared with performance status (ECOG) in patients (n¼109)
receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. On multivariate analysis with ECOG, white cell
count and the GPS entered as covariates, only the GPS was a significant independent predictor of survival (HR 1.88, 95% CI 1.25–
2.84, P¼0.002).
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Non-small-cell lung cancer (NSCLC) is the most common cause of
cancer death in North America and Western Europe. Most patients
present with advanced inoperable disease; the prognosis of these
patients is extremely poor. In selected patients, platinum-based
regimens have been shown to have a beneficial but modest impact
on survival (Klastersky and Paesmans, 2001). Conventionally, the
selection of patients for chemotherapy has been based on clinico-
pathological criteria, including age, stage and performance status
(Numico et al, 2001).
There is increasing evidence that the presence of a systemic
inflammatory response, as evidenced by elevated circulating
concentrations of C-reactive protein concentrations, is associated
with early recurrence and poor survival, independent of stage, in a
variety of common solid tumours (Ikeda et al, 2003; McMillan et al,
2003). In advanced disease, an elevated C-reactive protein has also
been shown to associated with poor survival (O’Gorman et al,
2000; Mahmoud and Rivera, 2002).
Furthermore, in an unselected cohort of patients with inoperable
NSCLC, the Glasgow Prognostic Score (GPS), a cumulative
prognostic score based on C-reactive protein and albumin, had
similar prognostic value to that of stage and performance status
(Forrest et al, 2003). The question of whether the GPS would be
useful in the selection of appropriate treatment for patients with
inoperable NSCLC remains to be determined.
The aim of the present study was to assess the value of the GPS
in patients receiving chemotherapy for inoperable NSCLC.
MATERIALS AND METHODS
Study design
Patients presenting with inoperable NSCLC (stages III and IV) to a
single multidisciplinary oncology clinic in Glasgow Royal Infirm-
ary between March 2000 and June 2003 were studied prospectively.
All patients had cytologically or histologically confirmed disease
and were staged on the basis of clinical findings, chest X-ray and,
where appropriate, bronchoscopy, liver ultrasound, isotope bone
scan and computerised tomography of the thorax, according to the
American Thoracic Society TNM classification (Mountain, 1991).
Clinical stage, tumour type and performance status (Eastern
Cooperative Oncology Group, ECOG) were recorded at the time of
diagnosis. A blood sample was also obtained for the measurement
of white cell count, albumin and C-reactive protein concentrations.
Patients received between one and six cycles of platinum-based
chemotherapy.
The study was approved by the Research Ethics Committee of
Glasgow Royal Infirmary.
Methods
Blood parameters: Routine laboratory measurements of albumin
and C-reactive protein concentration were carried out. The
coefficient of variation for these methods, over the range of
measurement, was less than 5% as established by routine quality
control procedures.
The GPS was constructed as previously described (Forrest et al,
2003). Briefly, patients with both an elevated C-reactive protein
(410mgl
 1) and hypoalbuminaemia (o35gl
 1) were allocated a
score of 2. Patients in whom only one of these biochemical
abnormalities was present were allocated a score of 1. Patients in
whom neither of these abnormalities was present were allocated a
score of 0.
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Univariate survival analysis was performed using the Kaplan–
Meier method with the log-rank test. Multivariate survival analysis
and calculation of hazard ratios (HR) were performed using Cox
regression analysis. Deaths up to 31st October 2003 were included
in the analysis. Analysis was performed using SPSS software (SPSS
Inc., Chicago, IL, USA).
RESULTS
The characteristics of patients with inoperable NSCLC receiving
platinum-based chemotherapy (n¼109) are shown in Table 1. The
majority were male and over the age of 60 years. Approximately
50% had stage III disease, 90% had an ECOG performance status of
0–1, 75% had an elevated C-reactive protein and 10% had
hypoalbuminaemia. The majority (68%) received cisplatin-based
chemotherapy and the remainder carboplatin-based chemother-
apy.
In total, 71 (65%) of patients died during the follow-up period.
On univariate survival analysis, both white cell count and GPS
were significant predictors of survival. Median survival times in
the groups with an ECOG of 0, 1 and 2 were 16, 12 and 7 months,
respectively, but were associated with wide confidence intervals
and the difference in survival was not significant (Figure 1A).
Median survival times in the groups with a GPS of 0, 1 and 2 were
17, 12 and 7 months respectively (Po0.01, Figure 1B).
On multivariate analysis with ECOG, white cell count and the
GPS entered as covariates, only the GPS was a significant
independent predictor of survival (HR 1.88, 95% CI 1.25–2.84,
P¼0.002).
DISCUSSION
Conventionally, in patients with inoperable NSCLC, the decision
whether or not to offer chemotherapy is primarily based on
performance status. However, the assessment of performance
status is subjective. For example, significant differences in the
assessment of performance status have been reported between
oncologists, nurses and patients, oncologists being the most
optimistic in their assessment and patients the least (Ando et al,
2001). As a result there is continuing interest in the development of
prognostic scores, which better reflect clinical outcome (Bennett
and Ryall, 2000; Sloan et al, 2001).
In the present study, an inflammation-based prognostic score
based on standard laboratory measurements, the GPS, appeared to
be superior to performance status in predicting outcome following
platinum-based chemotherapy. This may be in part because the
assessment of performance status reflects functional status at a
specific point in time. In contrast, the GPS, based as it is on the
presence of an ongoing systemic inflammatory response and
hypoalbuminaemia, predicts the progressive nutritional decline of
Table 1 Clinical characteristics and survival in patients with inoperable
NSCLC receiving platinum-based chemotherapy: univariate survival analysis
Patients Survival (months) P-value
109 (100%) Median (95% CI)
Age
o60 years 41 (38) 10.6 (3.8–17.3)
X60 years 68 (62) 13.5 (11.2–15.9) 0.681
Sex
Male 63 (58) 15.1 (11.0–19.2)
Female 46 (42) 10.6 (10.1–11.1) 0.433
Stage
III 52 (47) 13.5 (9.1–18.0)
IV 57 (52) 12.2 (7.8–16.6) 0.337
Type
Squamous 40 (37) 15.1 (7.9–22.4)
Adenocarcinoma 46 (42) 14.0 (9.5–18.6)
Other 23 (21) 11.7 (9.7–13.6) 0.192
Performance status (ECOG)
0 29 (27) 16.0 (9.2–22.7)
1 71 (65) 12.2 (9.9–14.5)
2 9 (8) 7.1 (1.7–12.4) 0.405
White cell count
o10 10
9/l 62 (56) 16.6 (13.1–20.1)
Z10 10
9/l 47 (44) 11.7 (9.4–14.0) 0.029
GPS
0 27 (25) 17.0 (14.0–19.9)
1 69 (63) 12.1 (10.0–14.1)
2 13 (12) 7.1 (4.9–9.2) 0.005
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Figure 1 (A) The relationship between ECOG performance status (0
yy., 1 —–, 2 _____) in patients with inoperable non-small-cell lung
cancer receiving platinum-based chemotherapy. (B) The relationship
between the GPS (0 yy., 1 —–, 2 _____) in patients with inoperable
non-small-cell lung cancer receiving platinum-based chemotherapy.
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lthe patient (McMillan et al, 2001; Scott et al, 2002). Indeed, it has
long been recognised that progressive weight loss is associated
with poor tolerance to chemotherapy (Chlebowski et al, 1996;
Paesmans et al, 1997).
More recently, it has been reported that cytochrome P450 3A
activity, the principal drug metabolising enzyme in a variety of
chemotherapeutic agents, is compromised in advanced lung cancer
patients with an elevated C-reactive protein concentration (Rivory
et al, 2002; Slaviero et al, 2003). One might therefore postulate that
the presence of a systemic inflammatory response would be
associated with increased toxicity in patients receiving platinum-
based chemotherapy. It was therefore of interest that 40% of
patients with a GPS of 0 received six cycles platinum-based
chemotherapy compared with only 9% of those with a GPS of 1 or
2( P¼0.003, Fisher’s exact test). This suggests that the presence of
a systemic inflammatory response may be an important factor in
determining the ability of patients to tolerate platinum-based
chemotherapy.
It is possible that in patients with inoperable non-small-lung
cancer, an elevated C-reactive protein concentration might reflect
intercurrent infection. If this were the case it might be expected
that the increase in circulating C-reactive protein concentrations
would be associated with a rise in the white cell count. However, in
the present study, although the white cell count was significantly
correlated with C-reactive protein concentrations, the magnitude
of the relationship was small (r
2¼10.6%). This would suggest that
infection was not the main stimulus to the increased C-reactive
protein concentrations.
The results of the present study suggest that the GPS offers
additional prognostic information that may assist in the selection
of appropriate patients with inoperable NSCLC for platinum-based
chemotherapy.
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